{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T15:09:49Z","timestamp":1766848189972,"version":"3.37.3"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2020,1,11]],"date-time":"2020-01-11T00:00:00Z","timestamp":1578700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,4,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Novel direct-acting antiviral agents have shown great efficacy and tolerability in HCV-monoinfected patients. However, data are lacking regarding their efficacy and safety in HIV\/HCV-genotype (GT) 4-coinfected patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A single-centre, prospective study including HIV\/HCV-GT 4-coinfected patients who were treated with sofosbuvir and daclatasvir (SOF\/DCV) was conducted for 12\u00a0wk. Sustained virological response (SVR) at week 12 post-treatment (SVR12), adverse events (AEs) and changes in liver stiffness measurement (LSM) at SVR12 in comparison with baseline were evaluated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>SVR12 was achieved in 46 of 50 patients (92%). No significant difference in SVR12 was noticed among patients who received antiretroviral therapy (ART) regimens compared with those who did not receive ART regimens or between those with insignificant fibrosis (&amp;lt;F2) and those with significant fibrosis (\u2265F2) (p=0.9 and p=0.3, respectively). AEs occurred in 45 (90%) patients. The most frequent AEs were fatigue, headache and nausea. No treatment-related serious AEs or deaths were reported. HIV control was not compromised. LSM, fibrosis 4 score and aspartate aminotransferase-to-platelet ratio index showed a significant decrease at SVR12 when compared with baseline (p=0.0004, p=0.0003 and\u00a0p&amp;lt;0.0001, respectively). Logistic regression analysis showed no association between baseline variables and SVR12 while significant fibrosis (\u2265F2) was the only baseline variable that was significantly associated with improvement of LSM at SVR12.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>SOF\/DCV achieved a high SVR12 and was well-tolerated in HIV\/HCV-GT 4-coinfected patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/trstmh\/trz120","type":"journal-article","created":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T20:12:22Z","timestamp":1572466342000},"page":"232-240","source":"Crossref","is-referenced-by-count":7,"title":["Sustained virologic response and changes in liver fibrosis parameters following 12-wk administration of generic sofosbuvir and daclatasvir in HIV\/HCV-coinfected patients with HCV genotype 4 infection"],"prefix":"10.1093","volume":"114","author":[{"given":"Ahmed","family":"Cordie","sequence":"first","affiliation":[{"name":"Endemic Medicine and Hepatology Department, Faculty of Medicine, Cairo University, Cairo 11562, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aisha","family":"Elsharkawy","sequence":"first","affiliation":[{"name":"Endemic Medicine and Hepatology Department, Faculty of Medicine, Cairo University, Cairo 11562, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3612-0130","authenticated-orcid":false,"given":"Shereen","family":"Abdel Alem","sequence":"first","affiliation":[{"name":"Endemic Medicine and Hepatology Department, Faculty of Medicine, Cairo University, Cairo 11562, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Safa","family":"Meshaal","sequence":"first","affiliation":[{"name":"Clinical pathology Department, Faculty of Medicine, Cairo University, Cairo 11562, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wafaa","family":"El Akel","sequence":"first","affiliation":[{"name":"Endemic Medicine and Hepatology Department, Faculty of Medicine, Cairo University, Cairo 11562, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeinab","family":"Abdellatif","sequence":"first","affiliation":[{"name":"Endemic Medicine and Hepatology Department, Faculty of Medicine, Cairo University, Cairo 11562, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walid","family":"Kamal","sequence":"first","affiliation":[{"name":"Preventive sector, Ministry of Health and Population, Cairo 11516, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud","family":"Al Askalany","sequence":"first","affiliation":[{"name":"Imbaba Fever Hospital, Ministry of Health and Population, Cairo 12651, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherif","family":"Kamel","sequence":"first","affiliation":[{"name":"Imbaba Fever Hospital, Ministry of Health and Population, Cairo 12651, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hossam","family":"Abdel Aziz","sequence":"first","affiliation":[{"name":"Department of Hepatology, Faculty of Medicine, Ain Shams University, Cairo 11591, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amr","family":"Kandeel","sequence":"first","affiliation":[{"name":"Preventive sector, Ministry of Health and Population, Cairo 11516, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gamal","family":"Esmat","sequence":"first","affiliation":[{"name":"Endemic Medicine and Hepatology Department, Faculty of Medicine, Cairo University, Cairo 11562, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,1,11]]},"reference":[{"key":"2020040802552263000_ref1"},{"key":"2020040802552263000_ref2","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/hiv.12502","article-title":"Liver-related mortality and hospitalizations attributable to chronic hepatitis C virus coinfection in persons living with HIV","volume":"18","author":"Mena","year":"2017","journal-title":"HIV Med."},{"key":"2020040802552263000_ref3","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/j.1365-2893.2009.01197.x","article-title":"HIV-HCV co-infected patients with low CD4 + cell nadirs are at risk for faster fibrosis progression and portal hypertension","volume":"17","author":"Reiberger","year":"2010","journal-title":"J Viral Hepatitis."},{"issue":"4","key":"2020040802552263000_ref4","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.3748\/wjg.v22.i4.1421","article-title":"New approaches in the treatment of hepatitis C","volume":"22","author":"Gonza'lez-Grande","year":"2016","journal-title":"World J Gastroenterol."},{"key":"2020040802552263000_ref5","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1002\/hep.29308","article-title":"High hepatitis C cure rates among black and non-black HIV-infected adults in an urban center","volume":"66","author":"Falade-Nwulia","year":"2017","journal-title":"Hepatology."},{"key":"2020040802552263000_ref6","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1056\/NEJMoa1503153","article-title":"Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1","volume":"373","author":"Wyles","year":"2015","journal-title":"N Engl J Med."},{"key":"2020040802552263000_ref7","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","article-title":"EASL recommendations on treatment of hepatitis C 2016","volume":"66","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J Hepatol."},{"issue":"suppl","key":"2020040802552263000_ref8","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jhep.2016.07.039","article-title":"Reversion of disease manifestations after HCV eradication","volume":"65","author":"van der Meer","year":"2016","journal-title":"J Hepatol."},{"issue":"9","key":"2020040802552263000_ref9","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1111\/jgh.13758","article-title":"Changes in liver stiffness measurements and fibrosis scores following Sofosbuvir based treatment regimens without interferon","volume":"32","author":"Elsharkawy","year":"2017","journal-title":"J Gastroenterol Hepatol."},{"key":"2020040802552263000_ref10","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3851\/IMP2674","article-title":"Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir","volume":"18","author":"Bifano","year":"2013","journal-title":"Antivir Ther."},{"key":"2020040802552263000_ref11","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med."},{"key":"2020040802552263000_ref12","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jhep.2008.02.008","article-title":"Noninvasive evaluation of liver fibrosis using transient elastography","volume":"48","author":"Castera","year":"2008","journal-title":"J Hepatol."},{"key":"2020040802552263000_ref13","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.ultrasmedbio.2003.07.001","article-title":"Transient elastography: a new noninvasive method for assessment of hepatic fibrosis","volume":"29","author":"Sandrin","year":"2003","journal-title":"Ultrasound Med Biol."},{"issue":"6","key":"2020040802552263000_ref14","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0399-8320(08)73994-0","article-title":"Transient elastography (FibroScan)","volume":"32","author":"De L\u00e9dinghen","year":"2008","journal-title":"Gastroenterol Clin Biol."},{"key":"2020040802552263000_ref15","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1053\/jhep.2003.50346","article-title":"A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C","volume":"38","author":"Wai","year":"2003","journal-title":"Hepatology."},{"key":"2020040802552263000_ref16","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis inpatients with HIV\/HCV co-infection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology."},{"issue":"10","key":"2020040802552263000_ref17","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1093\/jac\/dkq272","article-title":"Changes in liver stiffness in patients with chronic hepatitis C with and without HIV co-infection treated with pegylated interferon plus ribavirin","volume":"65","author":"Mac\u00edas","year":"2010","journal-title":"J Antimicrob Chemother."},{"key":"2020040802552263000_ref18","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature08960","article-title":"Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect","volume":"465","author":"Gao","year":"2010","journal-title":"Nature."},{"key":"2020040802552263000_ref19","doi-asserted-by":"crossref","first-page":"7202","DOI":"10.1021\/jm100863x","article-title":"Discovery of a b-d-2\u2032-deoxy-2\u2032- a-fluoro-2\u2032-b-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus","volume":"53","author":"Sofia","year":"2010","journal-title":"J Med Chem."},{"key":"2020040802552263000_ref20","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1097\/QAD.0000000000001020","article-title":"Interferon-free treatment with sofosbuvir\/daclatasvir achieves sustained virologic response in 100% of HIV\/hepatitis C virus-coinfected patients with advanced liver disease","volume":"30","author":"Mandorfer","year":"2016","journal-title":"AIDS."},{"key":"2020040802552263000_ref21","first-page":"225","article-title":"Full-dose sofosbuvir and daclatasvir for chronic hepatitis C infection in haemodialysis patients","volume":"74","author":"Gevers","year":"2016","journal-title":"Neth J Med."},{"key":"2020040802552263000_ref22","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1080\/15284336.2017.1330801","article-title":"HIV coinfected patients respond worse to direct-acting antiviral based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study","volume":"18","author":"Neukam","year":"2017","journal-title":"HIV Clin Trials"},{"key":"2020040802552263000_ref23","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/hiv.12429","article-title":"Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV\/HIV-coinfected patients: real-life safety and efficacy","volume":"18","author":"Milazzo","year":"2017","journal-title":"HIV Med."},{"issue":"2","key":"2020040802552263000_ref24","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S2468-1253(18)30382-0","article-title":"Treatment of chronic hepatitis C virus infection in Rwanda with ledipasvir-sofosbuvir (SHARED): a single-arm trial","volume":"4","author":"Gupta","year":"2019","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"3","key":"2020040802552263000_ref25","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3851\/IMP3108","article-title":"Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV-HCV coinfection and advanced liver disease","volume":"22","author":"Rockstroh","year":"2017","journal-title":"Antivir Ther."},{"issue":"12","key":"2020040802552263000_ref26","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1093\/cid\/ciw163","article-title":"12 weeks of Daclatasvir in combination with Sofosbuvir for HIV-HCV Coinfection (ALLY-2 study): efficacy and safety by HIV combination antiretroviral regimens","volume":"62","author":"Luetkemeyer","year":"2016","journal-title":"Clin Infect Dis."},{"issue":"8","key":"2020040802552263000_ref27","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/hiv.12632","article-title":"Liver stiffness reduction and serum fibrosis score improvement in HIV\/hepatitis C virus-coinfected patients treated with direct-acting antivirals","volume":"19","author":"Fabbri","year":"2018","journal-title":"HIV Med."},{"key":"2020040802552263000_ref28","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1053\/gast.2002.33023","article-title":"Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C","volume":"122","author":"Poynard","year":"2002","journal-title":"Gastroenterology."},{"key":"2020040802552263000_ref29","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1002\/hep.25791","article-title":"Hepatic steatosis and steatohepatitis in human immunodeficiency virus\/hepatitis C virus-coinfected patients","volume":"56","author":"Macias","year":"2012","journal-title":"Hepatology."},{"key":"2020040802552263000_ref30","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/jvh.12658","article-title":"More improvement than progression of liver fibrosis following antiretroviral therapy in a longitudinal cohort of HIV-infected patients with or without HBV and HCV co-infections","volume":"24","author":"Ding","year":"2017","journal-title":"J Viral Hepat."}],"container-title":["Transactions of The Royal Society of Tropical Medicine and Hygiene"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/trstmh\/article-pdf\/114\/4\/232\/33012924\/trz120.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/trstmh\/article-pdf\/114\/4\/232\/33012924\/trz120.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T06:55:48Z","timestamp":1586328948000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/trstmh\/article\/114\/4\/232\/5699686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,11]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,1,11]]},"published-print":{"date-parts":[[2020,4,8]]}},"URL":"https:\/\/doi.org\/10.1093\/trstmh\/trz120","relation":{},"ISSN":["0035-9203","1878-3503"],"issn-type":[{"type":"print","value":"0035-9203"},{"type":"electronic","value":"1878-3503"}],"subject":[],"published-other":{"date-parts":[[2020,4]]},"published":{"date-parts":[[2020,1,11]]}}}